To evaluate the ability of ladarixin, an inhibitor of the CXCR1/2 chemokine receptors (LDX, 400 mg b.i.d for 3 cycles of 14 days on/14 days off) to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.
Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial / Piemonti, Lorenzo; Keymeulen, Bart; Gillard, Pieter; Linn, Thomas; Bosi, Emanuele; Rose, Ludger; Pozzilli, Paolo; Giorgino, Francesco; Cossu, Efisio; Daffonchio, Luisa; Goisis, Giovanni; Ruffini, Pier Adelchi; Maurizi, Anna Rita; Mantelli, Flavio; Allegretti, Marcello. - In: DIABETES, OBESITY AND METABOLISM. - ISSN 1462-8902. - 24:9(2022), pp. 1840-1849. [10.1111/dom.14770]
Ladarixin, an inhibitor of IL-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: a multicenter, randomized, double-blind, placebo-controlled trial
Piemonti, Lorenzo
Primo
;Bosi, Emanuele;
2022-01-01
Abstract
To evaluate the ability of ladarixin, an inhibitor of the CXCR1/2 chemokine receptors (LDX, 400 mg b.i.d for 3 cycles of 14 days on/14 days off) to maintain C-peptide production in adult patients with newly diagnosed type 1 diabetes.| File | Dimensione | Formato | |
|---|---|---|---|
|
Diabetes Obesity Metabolism - 2022 - Piemonti - Ladarixin an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2 in.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
2.08 MB
Formato
Adobe PDF
|
2.08 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
